IRON Stock Analysis & IQ Rating | Disc Medicine

IRON Price Performance

IRON Analysts opinion is negative and it remained unchanged from the past 3 months

Date

Action

Rating

Firm

Nov 11, 2025

Reiterate

Buy

Truist Securities

Oct 31, 2025

Reiterate

Overweight

Morgan Stanley

Oct 18, 2025

Reiterate

Buy

Raymond James

Oct 18, 2025

Reiterate

Outperform

Wedbush

Oct 18, 2025

Reiterate

Overweight

Cantor Fitzgerald

FDA Delays Disc Medicines Rare Disease Drug. ) shares closed around 22% lower on Friday as a regulatory hiccup with a Complete Response Letter (CRL) from the United States Food and Drug Administration (FDA) regarding its drug bitopertin. On Tuesday the stock is trading higher.Bitopertin has been under review for accelerated approval and as part of the Commissioner’.s National Priority .In January FDA reviewers postponed their decision on bitopertin by about two weeks to February 10.Regulat

Today

Disc Medicine plunges on FDA Complete Response Letter for bitopertin.

Fri Feb 13, 2026

Drug For Rare Genetic Disorder Goes From FDA Priority to Reject in Four Months. The rejection of Disc Medicine Inc.s experimental compound for a rare and devastating disorder by the US Food and Drug Administration just months after it received a voucher intended to speed US reviews for breakthrough treatments is the latest example of the growing uncertainty at the nations top drug regulator.

Fri Feb 13, 2026

Disc Medicine is Now Oversold (IRON). Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which me

Fri Feb 13, 2026

Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP. WATERTOWN Mass. Feb. 13 2026 (GLOBE NEWSWIRE) -- Disc Medicine Inc. (NASDAQ:IRON) a biopharmaceutical company focused on the discovery development and commercialization of novel treatments for patients suffering from serious hematologic diseases announced that the United States Food and Drug Administration (FDA) today issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for bit

Fri Feb 13, 2026

Wall Street Analysts Believe Disc Medicine Inc. (IRON) Could Rally 48.62%: Heres is How to Trade. The consensus price target hints at a 48.6% upside potential for Disc Medicine Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wed Jan 28, 2026